AURORA, Colo. (Oct. 28, 2010) – A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.
T…
Proton beam therapy is safe and effective and may be superior to other conventional treatments for Stage I inoperable non-small cell lung cancer (NSCLC) patients, according to a study in the October issue of the International Journal of Radiation On…
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial…
Patients with the earliest form of the most common type of lung cancer are more than twice as likely to die of the disease within four years if they have a mutation in a well known cancer-causing gene, scientists have found. The study in the July 2 issue of the Journal of the National Cancer Institute also shows that lung cancer patients who both smoke and consume alcohol frequently are more likely to have the mutation.
In a demonstration of vaccine therapy’s potential for treating lung cancer, scientists report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated. Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases.